...
首页> 外文期刊>Journal of pharmacological sciences. >Irsogladine prevents monochloramine-induced gastric mucosal lesions by improving the decrease in mucosal blood flow due to the disturbance of nitric oxide synthesis in rats.
【24h】

Irsogladine prevents monochloramine-induced gastric mucosal lesions by improving the decrease in mucosal blood flow due to the disturbance of nitric oxide synthesis in rats.

机译:伊索拉定可通过改善大鼠一氧化氮合成的干扰而减少粘膜血流量的减少,从而预防一氯胺诱导的胃粘膜损伤。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The inhibitory effect of an anti-ulcer drug irsogladine [2,4-diamino-6-(2,5-dichlorophenyl)-s-triazine maleate] on monochloramine (NH(2)Cl)-induced gastric mucosal lesions and its mechanisms of action were clarified in rats. Irsogladine dose-dependently prevented the formation of gastric mucosal lesions induced by 60 mM NH(2)Cl. The mucosal protective effect of irsogladine was not influenced by capsaicin-sensitive sensory defunctionalization. On the other hand, its protective effect was diminished by the inhibitor of nitric oxide synthase N(G)-nitro-L-arginine methylester (L-NAME), but not by the inducible nitric oxide synthase selective inhibitor aminoguanidine. Irsogladine restored the NH(2)Cl-induced decrease in the gastric cGMP formation as an index of nitric oxide synthesis, while it alone had no influence on the cGMP formation in intact tissues. Pretreatment with L-NAME abolished the recovery of cGMP by irsogladine. Furthermore, irsogladine ameliorated the NH(2)Cl-induced decrease in gastric mucosal blood flow, which was also reversed by pretreatment with L-NAME. These findings suggest that the improvement of the decrease in mucosal blood flow subsequent to the disturbance of gastric nitric oxide synthesis is involved in the protective effect of irsogladine on gastric mucosal lesions caused by NH(2)Cl.
机译:抗溃疡药物伊索拉定[2,4-二氨基-6-(2,5-二氯苯基)-s-三嗪马来酸酯]对一氯胺(NH(2)Cl)诱导的胃粘膜损伤的抑制作用及其机制在大鼠中阐明了作用。 Irsogladine剂量依赖性地阻止了60 mM NH(2)Cl诱导的胃粘膜损伤的形成。辣椒素敏感的感官去官能化作用不影响伊索拉定的粘膜保护作用。另一方面,一氧化氮合酶N(G)-硝基-L-精氨酸甲酯(L-NAME)的抑制剂减弱了其保护作用,但诱导型一氧化氮合酶选择性抑制剂氨基胍未减弱其保护作用。 Irsogladine恢复了NH(2)Cl诱导的胃cGMP形成的减少,作为一氧化氮合成的指标,而单独使用它对完整组织中的cGMP形成没有影响。用L-NAME进行的预处理消除了伊索拉定对cGMP的恢复。此外,伊索拉定改善了NH(2)Cl诱导的胃粘膜血流减少,这也可以通过用L-NAME预处理逆转。这些发现表明,胃粘膜一氧化氮合成紊乱后粘膜血流减少的改善与伊索拉定对NH(2)Cl引起的胃粘膜损伤的保护作用有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号